Immunosuppression with mycophenolate mofetil attenuates the development of hypertension and albuminuria in deoxycorticosterone acetate-salt hypertensive rats

被引:37
|
作者
Boesen, Erika I. [1 ]
Williams, Douglas L. [1 ]
Pollock, Jennifer S. [1 ]
Pollock, David M. [1 ]
机构
[1] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA
基金
美国国家卫生研究院;
关键词
hypertension; kidney; macrophage; mineralocorticoid; T-lymphocyte; IMMUNE CELL INFILTRATION; ANGIOTENSIN-II; SENSITIVE HYPERTENSION; BLOOD-PRESSURE; RENAL DAMAGE; MINERALOCORTICOID RECEPTORS; ARTERIAL-PRESSURE; OXIDATIVE STRESS; T-CELL; KIDNEY;
D O I
10.1111/j.1440-1681.2010.05428.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P>1. The interplay between the immune and renin-angiotensin systems is emerging as a crucial factor in the development and progression of hypertension. The aim of the present study was to determine the involvement of immune cells in the hypertension and renal injury produced by a non-angiotensin II-dependent form of hypertension, namely deoxycorticosterone acetate (DOCA)-salt-induced hypertension, in rats. 2. Male Sprague-Dawley rats underwent uninephrectomy and received either a sustained-release pellet of DOCA s.c. and 0.9% NaCl (saline) to drink for 21 days or a placebo pellet and water to drink for 21 days. Additional groups of DOCA-salt- and placebo-treated rats were treated concurrently with the immune suppressant mycophenolate mofetil (MMF; 30 mg/kg per day). Rats were placed in metabolic cages for 24 h urine collection prior to and at weekly intervals during the 21 day experimental period. 3. Mycophenolate mofetil significantly attenuated the development of hypertension in DOCA-salt rats compared with untreated DOCA-salt hypertensive rats (mean arterial pressure by telemetry on Day 18 146 +/- 7 vs 180 +/- 3 mmHg, respectively; P < 0.001), as well as proteinuria (87 +/- 27 vs 305 +/- 63 mg/day, respectively, on Day 21) and albuminuria (51 +/- 15 vs 247 +/- 73 mg/day, respectively, on Day 21). Creatinine clearance was better preserved in MMF-treated DOCA-salt rats compared with untreated DOCA-salt rats (0.74 +/- 0.07 vs 0.49 +/- 0.09 mL/min, respectively; P < 0.05), but was still significantly reduced compared with that in the placebo group (1.15 +/- 0.12 mL/min; P < 0.05). Finally, MMF treatment significantly attenuated the DOCA-salt-induced rise in renal cortical T-lymphocyte and macrophage infiltration (P < 0.05). 4. These data indicate that immune cells play a deleterious role in both the hypertension and renal injury associated with DOCA-salt hypertension.
引用
收藏
页码:1016 / 1022
页数:7
相关论文
共 50 条
  • [31] Allopurinol Does Not Decrease Blood Pressure or Prevent the Development of Hypertension in the Deoxycorticosterone Acetate-Salt Rat Model
    Szasz, Theodora
    Elizabeth Linder, A.
    Davis, Robert P.
    Burnett, Robert
    Fink, Gregory D.
    Watts, Stephanie W.
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 56 (06) : 627 - 634
  • [32] Axl mediates vascular remodeling induced by deoxycorticosterone acetate-salt hypertension
    Korshunov, Vyacheslav A.
    Daul, Matthew
    Massett, Michael P.
    Berk, Bradford C.
    HYPERTENSION, 2007, 50 (06) : 1057 - 1062
  • [33] Effect of trichlormethiazide and captopril on nitric oxide synthase activity in the kidney of deoxycorticosterone acetate-salt hypertensive rats
    Takanohashi, A
    Tojo, A
    Kobayashi, N
    Yagi, S
    Matsuoka, H
    JAPANESE HEART JOURNAL, 1996, 37 (02): : 251 - 259
  • [34] Deoxycorticosterone acetate-salt hypertension activates placental growth factor in the spleen to couple sympathetic drive and immune system activation
    Perrotta, Marialuisa
    Lori, Andrea
    Carnevale, Lorenzo
    Fardella, Stefania
    Cifelli, Giuseppe
    Iacobucci, Roberta
    Mastroiacovo, Francesco
    Iodice, Daniele
    Pallante, Fabio
    Storto, Marianna
    Lembo, Giuseppe
    Carnevale, Daniela
    CARDIOVASCULAR RESEARCH, 2018, 114 (03) : 456 - 467
  • [35] Renal Damages in Deoxycorticosterone Acetate-Salt Hypertensive Rats: Assessment with Diffusion Tensor Imaging and T2-mapping
    Ko, Sheung-Fat
    Yip, Hon-Kan
    Zhen, Yen-Yi
    Hung, Chi-Chih
    Lee, Chen-Chang
    Huang, Chung-Cheng
    Ng, Shu-Hang
    Chen, Yi-Ling
    Lin, Jui-Wei
    MOLECULAR IMAGING AND BIOLOGY, 2020, 22 (01) : 94 - 104
  • [36] POLYAMINES, VASCULAR SMOOTH-MUSCLE, AND DEOXYCORTICOSTERONE ACETATE-SALT HYPERTENSION
    SOLTIS, EE
    NEWMAN, PS
    OLSON, JW
    HYPERTENSION, 1991, 18 (01) : 85 - 92
  • [37] Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate-salt hypertensive uni-nephrectomized KKAymice
    Nio, Yasunori
    Ookawara, Mitsugi
    Yamasaki, Midori
    Hanauer, Guido
    Tohyama, Kimio
    Shibata, Sachio
    Sano, Tomoya
    Shimizu, Fumi
    Anayama, Hisashi
    Hazama, Masatoshi
    Matsuo, Takanori
    FASEB JOURNAL, 2020, 34 (11) : 14997 - 15014
  • [38] Increased renal atrial natriuretic peptide synthesis in rats with deoxycorticosterone acetate-salt treatment
    Lee, YJ
    Shin, SJ
    Tan, MS
    Hsieh, TJ
    Tsai, JH
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL FLUID AND ELECTROLYTE PHYSIOLOGY, 1996, 271 (04): : F779 - F789
  • [39] Central action of increased osmolality to support blood pressure in deoxycorticosterone acetate-salt rats
    O'Donaughy, Theresa L.
    Qi, Yue
    Brooks, Virginia L.
    HYPERTENSION, 2006, 48 (04) : 658 - 663
  • [40] Mycophenolate mofetil attenuates pulmonary arterial hypertension in rats
    Suzuki, Chihiro
    Takahashi, Masafumi
    Morimoto, Hajime
    Izawa, Atsushi
    Ise, Hirohiko
    Hongo, Minoru
    Hoshikawa, Yasushi
    Ito, Takayuki
    Miyashita, Hiroshi
    Kobayashi, Eiji
    Shimada, Kazuyuki
    Ikeda, Uichi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 349 (02) : 781 - 788